Are Mast Cells Involved in Autoinflammatory Diseases

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients >18 years old with Auto-inflammatory diseases already followed up at the CeRéMAIA (french national reference center for autoinflamamtory diseases and AA amyloidosis) of Tenon hospital and included in the JIRcohorte

Healthy adult controls, age- and sex-matched with MAI patients, and controls with mastocytosis, an immuno-inflammatory disease.

Subject affiliated to or entitled to a social security scheme

Collection of the patient's or healthy control's non-opposition

Disqualifiers

Subjects unable to answer questions or express themselves

Subjects who do not speak French

Subject deprived of liberty or under legal protection.

Trial population

Inpatients and outpatients wil be recruited in tertiary university centres of the Assitance Publique des Hopitaux de Paris. Healthy controls will be recruited from volunteer healthcare workers in Assitance Publique des Hopitaux de Paris

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

590 Participants
are grouped into 6 trial groups

6

Trial groups

See each trial group below.

Group A: Patients with AID
Group B: Control patients with mastocytosis
Group C: Control patients with normal digestive biopsy
Group D: Control patients with renal biopsy
Group E: Control patients with inflammatory disease
Group F: Healthy control from healthcare workers

Trial outcomes

Primary outcomes

1

: presence of MCAS

presence of clinical and biological markers of MCAS

Time frame
at inclusion

Secondary outcomes

1

comparison of clinical symptoms of MC activation between groups

we will compare clinical symptoms of MC activation between AID patients and other groups

Time frame
at inclusion
2

MC mediators associated to AID

determine which MC mediators are elevated in AID and if they correlate with inflammation

Time frame
at inclusion
3

MC infiltration in biopsies from AID patients

we will study MC infiltration in digestive, renale and cutaneous biopsies from patients with AID and compare them with biopsies from the other groups from subgroups of patients who had a biopsy performed.

Time frame
at inclusion, retrospectively
4

basophilic polynuclear activation in AID patients

we will study basophilic polynuclear activation from blood samples of AID patients

Time frame
at inclusion, retrospectively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: